Literature DB >> 33239807

Burning questions about smouldering myeloma.

Sarah DeWeerdt.   

Abstract

Entities:  

Keywords:  Cancer; Health care; Therapeutics

Year:  2020        PMID： 33239807     DOI： 10.1038/d41586-020-03225-0

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  4 in total

1.  Smoldering multiple myeloma.

Authors:  R A Kyle; P R Greipp
Journal:  N Engl J Med       Date:  1980-06-12       Impact factor: 91.245

2.  Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma.

Authors:  María-Victoria Mateos; Miguel-Teodoro Hernández; Pilar Giraldo; Javier de la Rubia; Felipe de Arriba; Lucía López Corral; Laura Rosiñol; Bruno Paiva; Luis Palomera; Joan Bargay; Albert Oriol; Felipe Prosper; Javier López; Eduardo Olavarría; Nuria Quintana; José-Luis García; Joan Bladé; Juan-José Lahuerta; Jesús-F San Miguel
Journal:  N Engl J Med       Date:  2013-08-01       Impact factor: 91.245

3.  Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression.

Authors:  Mark Bustoros; Romanos Sklavenitis-Pistofidis; Jihye Park; Robert Redd; Benny Zhitomirsky; Andrew J Dunford; Karma Salem; Yu-Tzu Tai; Shankara Anand; Tarek H Mouhieddine; Selina J Chavda; Cody Boehner; Liudmila Elagina; Carl Jannes Neuse; Justin Cha; Mahshid Rahmat; Amaro Taylor-Weiner; Eliezer Van Allen; Shaji Kumar; Efstathis Kastritis; Ignaty Leshchiner; Elizabeth A Morgan; Jacob Laubach; Tineke Casneuf; Paul Richardson; Nikhil C Munshi; Kenneth C Anderson; Lorenzo Trippa; François Aguet; Chip Stewart; Meletios-Athanasios Dimopoulos; Kwee Yong; P Leif Bergsagel; Salomon Manier; Gad Getz; Irene M Ghobrial
Journal:  J Clin Oncol       Date:  2020-05-22       Impact factor: 50.717

4.  Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma.

Authors:  Sagar Lonial; Susanna Jacobus; Rafael Fonseca; Matthias Weiss; Shaji Kumar; Robert Z Orlowski; Jonathan L Kaufman; Abdulraheem M Yacoub; Francis K Buadi; Timothy O'Brien; Jeffrey V Matous; Daniel M Anderson; Robert V Emmons; Anuj Mahindra; Lynne I Wagner; Madhav V Dhodapkar; S Vincent Rajkumar
Journal:  J Clin Oncol       Date:  2019-10-25       Impact factor: 44.544
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.